News

Axios on MSN1h
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
BioPharma Dive1h
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer ...
STAT2h
New CBER Director Vinay Prasad praises evidence, FDA reviewers in first speech to staff
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
The FDA names a new vaccine chief with an unsettling record, joining a controversial team
Dr. Vinay Prasad, the FDA's new vaccine chief, has been accused of spreading misinformation about Covid vaccines.
The American Journal of Managed Care19h
Biotech Stocks Slide After FDA Selects Prasad to Lead CBER
The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...
STAT2h
Judge deals blow to compounding pharmacies
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
Daily Express US on MSN21h
Covid vaccine skeptic put in charge of US shot program as FDA picks new chief
Prasad was an outspoken critic of vaccines, lockdowns and mask mandates during the Covid pandemic. In 2022, Prasad and Makary ...